Simeon I. Taylor
YOU?
Author Swipe
View article: <b>Metabolic Improvements with Tirzepatide in Lipodystrophy: A Novel Option?</b>
<b>Metabolic Improvements with Tirzepatide in Lipodystrophy: A Novel Option?</b> Open
Objective: Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodyst…
View article: <b>Metabolic Improvements with Tirzepatide in Lipodystrophy: A Novel Option?</b>
<b>Metabolic Improvements with Tirzepatide in Lipodystrophy: A Novel Option?</b> Open
Objective: Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodyst…
View article: 6652 Precision Diagnostic Approaches for Assessing Clinical Vitamin D Status
6652 Precision Diagnostic Approaches for Assessing Clinical Vitamin D Status Open
Disclosure: Z. Shahidzadeh Yazdi: None. E.A. Streeten: None. H.B. Whitlatch: Grant Recipient; Self; Regeneron Pharmaceuticals. M.E. Montasser: Grant Recipient; Self; Regeneron Pharmaceuticals. A.L. Beitelshees: None. S.I. Taylor: Consultin…
View article: 7255 Tirzepatide Helps Achieve Glycemic Control and Lower Triglycerides in Seven Patients with Lipodystrophy
7255 Tirzepatide Helps Achieve Glycemic Control and Lower Triglycerides in Seven Patients with Lipodystrophy Open
Disclosure: R. Meral: None. E.D. Frontera: None. M. Celik Guler: None. M.C. Foss de Freitas: None. N. Nachawi: None. D.T. Broome: Consulting Fee; Self; Tayco, Inc.. Research Investigator; Self; Novo Nordisk, Fractyl Laboratories, Rhythm Ph…
View article: Evolving Approaches for Pharmacological Therapy of Obesity
Evolving Approaches for Pharmacological Therapy of Obesity Open
Obesity is a global health concern. Progress in understanding the physiology of obesity and weight reduction has provided new drug targets. Development and testing of new antiobesity medications (AOMs) has the potential to quickly expand o…
View article: Tirzepatide for Lipodystrophy
Tirzepatide for Lipodystrophy Open
Background Lipodystrophy encompasses a group of rare disorders associated with severe metabolic disease. These disorders are defined by abnormal fat distribution, with near-total (generalized lipodystrophy, GL) or partial (partial lipodyst…
View article: Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D Status
Value of Vitamin D Metabolite Ratios in 3 Patients as Diagnostic Criteria to Assess Vitamin D Status Open
Although clinical guidelines recommend measuring total plasma 25-hydroxyvitamin D (25[OH]D) to assess vitamin D (VitD) status, this index does not account for 3-fold inter-individual variation in VitD binding protein (VDBP) level. We prese…
View article: Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test
Acute pharmacodynamic responses to sitagliptin: Drug‐induced increase in early insulin secretion in oral glucose tolerance test Open
DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses. Sitagliptin (…
View article: ASSOCIATION OF DIABETES AND VAGINAL MICROBIOTA WITH THE GENITOURINARY SYNDROME OF MENOPAUSE
ASSOCIATION OF DIABETES AND VAGINAL MICROBIOTA WITH THE GENITOURINARY SYNDROME OF MENOPAUSE Open
The genitourinary syndrome of menopause (GSM) comprises urogenital signs and symptoms associated with estrogen deficiency during menopause. For many, decreased estrogen reduces vaginal Lactobacillus species abundance, a state associated wi…
View article: THU397 Homeostatic Regulation Of 1,25-dihydroxyvitamin D: Critical Role Of 24-hydroxylation (CYP24A1)
THU397 Homeostatic Regulation Of 1,25-dihydroxyvitamin D: Critical Role Of 24-hydroxylation (CYP24A1) Open
Disclosure: Z. Shahidzadeh Yazdi: None. E.A. Streeten: Grant Recipient; Self; Regeneron Pharmaceuticals. H.B. Whitlatch: Grant Recipient; Self; Regeneron Pharmaceuticals. M.E. Montasser: Grant Recipient; Self; Regeneron Pharmaceuticals. A.…
View article: Acute pharmacodynamic responses to sitagliptin: Drug-induced increase in early insulin secretion in oral glucose tolerance test
Acute pharmacodynamic responses to sitagliptin: Drug-induced increase in early insulin secretion in oral glucose tolerance test Open
Aim DPP4 inhibitors are widely prescribed as treatments for type 2 diabetes. Because drug responses vary among individuals, we initiated investigations to identify genetic variants associated with the magnitude of drug responses. Methods S…
View article: Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH
Vitamin D Deficiency Increases Vulnerability to Canagliflozin-induced Adverse Effects on 1,25-Dihydroxyvitamin D and PTH Open
Context Canagliflozin has been reported to increase the risk of bone fracture—possibly mediated by decreasing 1,25-dihydroxyvitamin D (1,25(OH)2D) and increasing parathyroid hormone (PTH). Objective This work investigated whether baseline …
View article: Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker
Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker Open
Aim To validate pharmacodynamic responses to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and test for association with genetic variants in SLC5A4 , SLC5A9 , and SLC2A9 . Methods Canagliflozin (300 mg), a SGLT2 inhibitor, was adminis…
View article: Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism
Critical Role for 24-Hydroxylation in Homeostatic Regulation of Vitamin D Metabolism Open
Context The body has evolved homeostatic mechanisms to maintain free levels of Ca +2 and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] within narrow physiological ranges. Clinical guidelines emphasize important contributions of PTH in maintaining…
View article: Acute pharmacodynamic responses to exenatide: Drug‐induced increases in insulin secretion and glucose effectiveness
Acute pharmacodynamic responses to exenatide: Drug‐induced increases in insulin secretion and glucose effectiveness Open
Aim Glucagon‐like peptide‐1 receptor agonists provide multiple benefits to patients with type 2 diabetes, including improved glycaemic control, weight loss and decreased risk of major adverse cardiovascular events. Because drug responses v…
View article: Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH
Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH Open
Context. Canagliflozin has been reported to increase the risk of bone fracture – possibly mediated by decreasing 1,25-dihydroxyvitamin D [1,25(OH) 2 D] and increasing PTH. Objective. To investigate whether baseline vitamin D (VitD) deficie…
View article: Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness
Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness Open
Background GLP1R agonists provide multiple benefits to patients with type 2 diabetes – including improved glycemic control, weight loss, and decreased risk of major adverse cardiovascular events. Because drug responses vary among individua…
View article: Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker Open
Aim SGLT2 inhibitors provide multiple benefits to patients with type 2 diabetes – including improved glycemic control and decreased risks of cardiorenal disease. Because drug responses vary among individuals, we initiated investigations to…
View article: Pharmacological treatment of hyperglycemia in type 2 diabetes
Pharmacological treatment of hyperglycemia in type 2 diabetes Open
Diabetes mellitus is a major public health problem, affecting about 10% of the population. Pharmacotherapy aims to protect against microvascular complications, including blindness, end-stage kidney disease, and amputations. Landmark clinic…
View article: YIPF5 mutations cause neonatal diabetes and microcephaly: progress for precision medicine and mechanistic understanding
YIPF5 mutations cause neonatal diabetes and microcephaly: progress for precision medicine and mechanistic understanding Open
Identifying genes that result in monogenic diabetes can provide insights that can build a scientific foundation for precision medicine. At present, nearly 20% of neonatal diabetes cases have unknown causes. In this issue of the JCI, De Fra…
View article: The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients
The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients Open
> The arc of the moral universe is long, but it bends toward justice.
>
> —Martin Luther King, Jr.
Diabetes exacts a high cost in human suffering, including increased burdens of cardiovascular disease, blindness, end-stage kidney disease…
View article: The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide Open
Summary A patient with atypical partial lipodystrophy who had a transient initial response to metreleptin experienced acute worsening of her metabolic state when neutralizing antibodies against metreleptin appeared. Because her metabolic s…
View article: Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin”
Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin” Open
Letter to the Editor: “Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin” Simeon I Taylor Simeon I Taylor University of Maryland School of Medicine, Department of Medicine, D…
View article: Genetic and functional evidence relates a missense variant in<i>B4GALT1</i>to lower LDL-C and fibrinogen
Genetic and functional evidence relates a missense variant in<i>B4GALT1</i>to lower LDL-C and fibrinogen Open
Increased LDL-cholesterol (LDL-C) and fibrinogen are independent risk factors for cardiovascular disease (CVD). We identified novel associations between an Amish-enriched missense variant (p.Asn352Ser) in a functional domain of beta-1,4-ga…